China faces approximately 4.8 million new cancer cases annually, making it one of the countries with the heaviest cancer burden globally. However, China has also made remarkable progress in cancer treatment—PD-1 inhibitors cost only 1/10 of US prices, CAR-T cell therapy costs about 1/5 of US prices, and targeted drugs have become much more accessible. For cancer patients considering second opinions or treatment in China, this article introduces four verifiable top oncology specialists.
China’s Advantages in Cancer Treatment
Immunotherapy Accessibility: Over 10 domestic PD-1/PD-L1 inhibitors have been approved in China, with annual treatment costs of approximately $7,000-21,000—only 1/10 to 1/5 of comparable US drugs. Domestic CAR-T products cost about $167,000, compared to $400,000-500,000 in the US.
Targeted Therapy: China is on par with international standards in targeted therapy for common cancers such as lung, liver, and gastric cancer. Domestic targeted drugs like icotinib (lung cancer), apatinib (gastric cancer), and zanubrutinib (lymphoma) are included in medical insurance.
Surgical Volume: China’s top cancer hospitals rank among the world’s highest in annual surgical volume. The Cancer Hospital of CAMS performs over 30,000 surgeries annually, while Sun Yat-sen University Cancer Center handles over one million outpatient visits per year.
5-Year Survival Comparison: China’s overall cancer 5-year survival rate has improved from 30.9% a decade ago to 40.5%, though still below the US rate of 67%. However, the gap is narrowing for certain cancers—China’s esophageal cancer 5-year survival is 29.7% (US 20%), and gastric cancer 35.1% (US 33%).
Top Oncology Specialists
1. Dr. Xu Ruihua (徐瑞华), Academician—Creator of China’s GI Cancer Immunotherapy Protocol
Basic Information: – Hospital: Sun Yat-sen University Cancer Center – Title: Academician of CAE, Chief Physician, Professor, President – Director of State Key Laboratory of Oncology in South China
Areas of Expertise: – GI cancers: Esophageal, gastric, colorectal cancer – Immunotherapy: PD-1 combination chemotherapy innovation – Targeted therapy: Dual-target combination immunotherapy
Key Achievements and Data: – Created strategies to overcome immunotherapy resistance; pioneered China’s GI cancer immunotherapy protocols achieving the world’s best outcomes – Doubled long-term survival for advanced esophageal/gastric cancer – Achieved over 40% 5-year survival for advanced colorectal cancer – Facilitated FDA/EMA approval of domestic PD-1 antibody combinations—a historic breakthrough for Chinese biologics – Published 210+ papers as corresponding author in NEJM, JAMA (2), BMJ, Nature Medicine (5), Cancer Cell (4) – Ranked as Highly Cited Researcher for 3 consecutive years; findings incorporated into 85 international/national guidelines – Received 2 National Science and Technology Progress Awards – Source: Sun Yat-sen University Cancer Center official website, Xinhua News Agency
Ideal for: – Advanced esophageal, gastric, or colorectal cancer patients seeking immunotherapy – GI cancer patients seeking second opinions – Patients interested in international multi-center clinical trials
2. Dr. Han Baohui (韩宝惠), Chief Physician—Lung Cancer Targeted Therapy Pioneer
Basic Information: – Hospital: Shanghai Chest Hospital / Shanghai Gobroad Hospital – Title: Chief Physician, Professor, Doctoral Supervisor
Areas of Expertise: – Lung cancer: Comprehensive treatment across all stages – Targeted therapy: EGFR, ALK and other driver mutation-positive lung cancer – Combination immunotherapy: PD-1/PD-L1 combined with chemotherapy or targeted therapy
Key Achievements and Data: – Among the first specialists in China to pioneer lung cancer targeted therapy and molecular epidemiology research – Over 40 years of clinical experience in lung cancer diagnosis and treatment – Actively involved in clinical trials of multiple domestic lung cancer targeted and immunotherapy drugs – Source: Shanghai Gobroad Hospital official website
Ideal for: – Newly diagnosed lung cancer patients seeking precision treatment plans – EGFR/ALK driver mutation-positive lung cancer patients needing targeted therapy – Advanced lung cancer patients considering immunotherapy
3. Dr. He Jie (赫捷), Academician—China’s Thoracic Surgery Leader
Basic Information: – Hospital: Cancer Hospital of Chinese Academy of Medical Sciences – Title: Academician of CAS, Chief Physician, Professor, President – Director of National Cancer Center
Areas of Expertise: – Thoracic tumors: Lung cancer, esophageal cancer – Minimally invasive thoracic surgery: VATS, robot-assisted thoracic surgery – Comprehensive esophageal cancer treatment
Key Achievements and Data: – Cancer Hospital of CAMS performs over 30,000 surgeries annually; thoracic surgery ranked #1 nationally – Pioneering contributions to minimally invasive surgical treatment of lung and esophageal cancer – Led the National Cancer Center in developing multiple Chinese cancer diagnosis and treatment guidelines – Source: Cancer Hospital of CAMS official website, National Cancer Center
Ideal for: – Early-stage lung cancer patients requiring surgical treatment – Esophageal cancer patients needing surgical intervention – Thoracic tumor patients seeking multidisciplinary treatment
4. Dr. Zhou Jun (周军), Chief Physician—Liver Cancer Precision Treatment Specialist
Basic Information: – Hospital: Peking University Cancer Hospital – Title: Chief Physician, Professor – Department of GI Medical Oncology
Areas of Expertise: – Liver cancer: Systemic treatment for advanced hepatocellular carcinoma – GI tumors: Cholangiocarcinoma, pancreatic cancer – Immunotherapy combined with targeted therapy
Key Achievements and Data: – Extensive clinical experience in immunotherapy plus targeted therapy for advanced HCC – Participated in multiple clinical studies of domestic innovative drugs for liver cancer – Discussed novel immune modulation mechanisms of etrumadenant combination antibodies on Xinhua Net in 2026 – Source: Xinhua News Agency, Peking University Cancer Hospital official website
Ideal for: – Advanced liver cancer patients seeking systemic treatment – Patients with cholangiocarcinoma, pancreatic cancer, or other difficult-to-treat GI tumors – Patients interested in novel immunotherapy combination regimens
Cost Reference for Cancer Treatment in China
| Treatment | China Cost (USD) | US Cost (USD) | Savings |
|---|---|---|---|
| PD-1 Inhibitor (annual) | $7,000-21,000 | $150,000-200,000 | ~90% |
| CAR-T Therapy | ~$167,000 | $400,000-500,000 | ~80% |
| Lung Cancer Targeted Drug (annual) | $4,200-13,900 | $100,000-200,000 | ~85% |
| Lung Cancer Surgery | $7,000-13,900 | $50,000-100,000 | ~85% |
| Radiation Therapy (full course) | $4,200-11,100 | $30,000-80,000 | ~90% |
Note: Prices are reference estimates. Actual costs vary by condition, treatment plan, and hospital tier. Some domestic drugs are covered by Chinese medical insurance, which international patients may not be eligible for.
Recommendations for International Patients
Pathology Review: Bring pathology slides and reports to a top Chinese cancer hospital for pathology consultation to ensure diagnostic accuracyGenetic Testing: Chinese cancer hospitals offer comprehensive genetic testing (NGS panels) for approximately $417-1,111, far less than in the USMultidisciplinary Team (MDT): Top Chinese cancer centers routinely use MDT approaches, with surgeons, medical oncologists, radiation oncologists, and pathologists collaborating on treatment plansClinical Trials: China has a large number of active oncology clinical trials; international patients can inquire about eligibility
